Aurobindo Pharma is planning to launch 19 approved products that have an addressable market of $6.8 billion in the US in the next three quarters. Moreover, the company has another 22 targeted ‘action dates through the end of the financial year’ although it does not ‘anticipate all those will be final approvals but a significant number will be’.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
